These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 19378679)

  • 21. Prolonged dual antiplatelet therapy improves clinical outcomes in high-risk patients implanted with sirolimus-eluting stents.
    Dean J; Yujie Z; Yingxin Z; Yuyang L; Yonghe G; Wanjun C; Zheng C
    Clin Cardiol; 2009 Mar; 32(3):164-8. PubMed ID: 19301293
    [TBL] [Abstract][Full Text] [Related]  

  • 22. 6- Versus 24-Month Dual Antiplatelet Therapy After Implantation of Drug-Eluting Stents in Patients Nonresistant to Aspirin: Final Results of the ITALIC Trial (Is There a Life for DES After Discontinuation of Clopidogrel).
    Didier R; Morice MC; Barragan P; Noryani AAL; Noor HA; Majwal T; Hovasse T; Castellant P; Schneeberger M; Maillard L; Bressolette E; Wojcik J; Delarche N; Blanchard D; Jouve B; Ormezzano O; Paganelli F; Levy G; Sainsous J; Carrie D; Furber A; Berlan J; Darremont O; Le Breton H; Lyuycx-Bore A; Gommeaux A; Cassat C; Kermarrec A; Cazaux P; Druelles P; Dauphin R; Armengaud J; Dupouy P; Champagnac D; Ohlmann P; Ben Amer H; Kiss RG; Ungi I; Gilard M
    JACC Cardiovasc Interv; 2017 Jun; 10(12):1202-1210. PubMed ID: 28641840
    [TBL] [Abstract][Full Text] [Related]  

  • 23. 5-year follow-up after primary percutaneous coronary intervention with a paclitaxel-eluting stent versus a bare-metal stent in acute ST-segment elevation myocardial infarction: a follow-up study of the PASSION (Paclitaxel-Eluting Versus Conventional Stent in Myocardial Infarction with ST-Segment Elevation) trial.
    Vink MA; Dirksen MT; Suttorp MJ; Tijssen JG; van Etten J; Patterson MS; Slagboom T; Kiemeneij F; Laarman GJ
    JACC Cardiovasc Interv; 2011 Jan; 4(1):24-9. PubMed ID: 21251625
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of Aspirin and Clopidogrel Hyporesponsiveness in Patients Treated With Drug-Eluting Stents: 2-Year Results of a Prospective, Multicenter Registry Study.
    Stuckey TD; Kirtane AJ; Brodie BR; Witzenbichler B; Litherland C; Weisz G; Rinaldi MJ; Neumann FJ; Metzger DC; Henry TD; Cox DA; Duffy PL; Mazzaferri EL; Gurbel PA; Mehran R; Généreux P; Ben-Yehuda O; Simonton CA; Stone GW;
    JACC Cardiovasc Interv; 2017 Aug; 10(16):1607-1617. PubMed ID: 28780034
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A new era of prospective real-world safety evaluation primary report of XIENCE V USA (XIENCE V Everolimus Eluting Coronary Stent System condition-of-approval post-market study).
    Krucoff MW; Rutledge DR; Gruberg L; Jonnavithula L; Katopodis JN; Lombardi W; Mao VW; Sharma SK; Simonton CA; Tamboli HP; Wang J; Wilburn O; Zhao W; Sudhir K; Hermiller JB
    JACC Cardiovasc Interv; 2011 Dec; 4(12):1298-309. PubMed ID: 22192371
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact of duration of clopidogrel prescription on outcome of DES as compared to BMS in primary angioplasty: a meta-regression analysis of randomized trials.
    De Luca G; Cassetti E; Marino P
    J Thromb Thrombolysis; 2009 May; 27(4):365-78. PubMed ID: 18498003
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antiplatelet therapy discontinuation following drug-eluting stent placement: dangers, reasons, and management recommendations.
    Moussa ID; Colombo A
    Catheter Cardiovasc Interv; 2009 Dec; 74(7):1047-54. PubMed ID: 19626692
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The three year follow-up of the randomised "all-comers" trial of a biodegradable polymer biolimus-eluting stent versus permanent polymer sirolimus-eluting stent (LEADERS).
    Wykrzykowska J; Serruys P; Buszman P; Linke A; Ischinger T; Klauss V; Eberli F; Corti R; Wijns W; Morice MC; Di Mario C; Van Geuns RJ; Van Es GA; Juni P; Windecker S
    EuroIntervention; 2011 Nov; 7(7):789-95. PubMed ID: 22027687
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-term safety and efficacy with paclitaxel-eluting stents: 5-year final results of the TAXUS IV clinical trial (TAXUS IV-SR: Treatment of De Novo Coronary Disease Using a Single Paclitaxel-Eluting Stent).
    Ellis SG; Stone GW; Cox DA; Hermiller J; O'Shaughnessy C; Mann T; Turco M; Caputo R; Bergin PJ; Bowman TS; Baim DS;
    JACC Cardiovasc Interv; 2009 Dec; 2(12):1248-59. PubMed ID: 20129552
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sex Differences in the Clinical Impact of High Platelet Reactivity After Percutaneous Coronary Intervention With Drug-Eluting Stents: Results From the ADAPT-DES Study (Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents).
    Yu J; Mehran R; Baber U; Ooi SY; Witzenbichler B; Weisz G; Rinaldi MJ; Neumann FJ; Metzger DC; Henry TD; Cox DA; Duffy PL; Mazzaferri EL; Brodie BR; Stuckey TD; Maehara A; Xu K; Ben-Yehuda O; Kirtane AJ; Stone GW
    Circ Cardiovasc Interv; 2017 Feb; 10(2):. PubMed ID: 28193677
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison between sirolimus- and paclitaxel-eluting stents in complex patient and lesions subsets.
    Roy P; Torguson R; Okabe T; Pinto Slottow TL; Steinberg DH; Smith K; Xue Z; Gevorkian N; Satler LL; Kent KM; Suddath WO; Pichard AD; Waksman R
    Catheter Cardiovasc Interv; 2007 Aug; 70(2):167-72. PubMed ID: 17503503
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Influence of low-dose aspirin (81 mg) on the incidence of definite stent thrombosis in patients receiving bare-metal and drug-eluting stents.
    Lotfi A; Cui J; Wartak S; Columbo J; Mulvey S; Davis M; Schweiger M; Giugliano GR
    Clin Cardiol; 2011 Sep; 34(9):567-71. PubMed ID: 21792981
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Duration of dual antiplatelet therapy after implantation of drug-eluting stents.
    Park SJ; Park DW; Kim YH; Kang SJ; Lee SW; Lee CW; Han KH; Park SW; Yun SC; Lee SG; Rha SW; Seong IW; Jeong MH; Hur SH; Lee NH; Yoon J; Yang JY; Lee BK; Choi YJ; Chung WS; Lim DS; Cheong SS; Kim KS; Chae JK; Nah DY; Jeon DS; Seung KB; Jang JS; Park HS; Lee K
    N Engl J Med; 2010 Apr; 362(15):1374-82. PubMed ID: 20231231
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The relative safety and efficacy of bare-metal and drug-eluting stents in low and high-risk patient subsets. An epidemiological analysis of three sequential cohorts of consecutive all comers (n = 6129).
    Daemen J; van Twisk PH; Kukreja N; van Domburg RT; Boersma E; de Jaegere P; Serruys PW
    EuroIntervention; 2009 Jan; 4(4):464-74. PubMed ID: 19284068
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Randomized comparison of everolimus-eluting stents and sirolimus-eluting stents in patients with ST elevation myocardial infarction: RACES-MI trial.
    Di Lorenzo E; Sauro R; Varricchio A; Capasso M; Lanzillo T; Manganelli F; Carbone G; Lanni F; Pagliuca MR; Stanco G; Rosato G; Suryapranata H; De Luca G
    JACC Cardiovasc Interv; 2014 Aug; 7(8):849-56. PubMed ID: 25147029
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long-term clinical outcome of rotational atherectomy followed by drug-eluting stent implantation in complex calcified coronary lesions.
    Abdel-Wahab M; Baev R; Dieker P; Kassner G; Khattab AA; Toelg R; Sulimov D; Geist V; Richardt G
    Catheter Cardiovasc Interv; 2013 Feb; 81(2):285-91. PubMed ID: 22431433
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Double antiplatelet therapy after drug-eluting stent implantation: risk associated with discontinuation within the first year.
    Ferreira-González I; Marsal JR; Ribera A; Permanyer-Miralda G; García-Del Blanco B; Martí G; Cascant P; Masotti-Centol M; Carrillo X; Mauri J; Batalla N; Larrousse E; Martín E; Serra A; Rumoroso JR; Ruiz-Salmerón R; de la Torre JM; Cequier A; Gómez-Hospital JA; Alfonso F; Martín-Yuste V; Sabatè M; García-Dorado D
    J Am Coll Cardiol; 2012 Oct; 60(15):1333-9. PubMed ID: 22999716
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-term follow-up (four years) of unprotected left main coronary artery disease treated with paclitaxel-eluting stents (from the TRUE Registry).
    Godino C; Parodi G; Furuichi S; Latib A; Barbagallo R; Goktekin O; Cera M; Mueller R; Tamburino C; Grube E; Di Mario C; Reimers B; Chieffo A; Antoniucci D; Colombo A; Sangiorgi GM
    EuroIntervention; 2010 Apr; 5(8):906-16. PubMed ID: 20542775
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical follow-up 3 years after everolimus- and paclitaxel-eluting stents: a pooled analysis from the SPIRIT II (A Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions) and SPIRIT III (A Clinical Evaluation of the Investigational Device XIENCE V Everolimus Eluting Coronary Stent System [EECSS] in the Treatment of Subjects With De Novo Native Coronary Artery Lesions) randomized trials.
    Caixeta A; Lansky AJ; Serruys PW; Hermiller JB; Ruygrok P; Onuma Y; Gordon P; Yaqub M; Miquel-Hebert K; Veldhof S; Sood P; Su X; Jonnavithula L; Sudhir K; Stone GW;
    JACC Cardiovasc Interv; 2010 Dec; 3(12):1220-8. PubMed ID: 21232715
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Late clinical outcomes after implantation of drug-eluting stents coated with biodegradable polymers: 3-year follow-up of the PAINT randomised trial.
    Lemos PA; Moulin B; Perin MA; Oliveira LA; Arruda JA; Lima VC; Lima AA; Caramori PR; Medeiros CR; Barbosa MR; Brito FS; Ribeiro EE
    EuroIntervention; 2012 May; 8(1):117-9. PubMed ID: 22580255
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.